rynotheknife > I think PFE's full year "pause" was a red herring
Well, yes, they clearly had undisclosed reasons for the extended delay to the trial restart.
Perhaps waiting for more data on the already threated patients, to decide if to restart the trial or abort i.
Or they wanted SGMO's valuation to drop while considering making or modifying a deal with SGMO.
Or...
But in any case, restarting the trial is obviously good news. Apparently PFE doesn't share your thesis " that ABR will likely be a trial-buster " . We shell see